Hagens Berman Sobol Shapiro has started an investigation into Medline Inc. for possibly misleading investors about its manufacturing quality controls and FDA compliance. The probe follows an FDA warning citing repeated contamination issues and inadequate corrective actions, which led to facility shutdowns and a $2.2 billion market value loss. The investigation aims to determine if Medline concealed these problems from investors. Investors with losses or relevant information are encouraged to come forward as the case develops.
Secret Network is proposing to migrate its SCRT token from the Cosmos blockchain to Ethereum's Arbitrum Layer 2, citing security vulnerabilities in its aging Cosmos code that are increasingly exposed to AI-powered exploits. This move follows a $4.7 m...
OpenAI announced the public launch of its GPT-5.6 AI model family, including Sol, Terra, and Luna, scheduled for Thursday. Sol is the most advanced model, Terra offers mid-level performance at half the cost, and Luna targets budget-conscious users. T...
Anaqua has renewed its partnership with Sony to enhance the strategic role of intellectual property (IP) in Sony's business growth and innovation. Since 2018, Anaqua has supported Sony in managing its global IP assets, including patents and trademark...
Anaqua has renewed its partnership with Sony to support the company's intellectual property (IP) management and innovation strategy. Since 2018, Anaqua has provided Sony with its IP management platform and services, and the renewed agreement includes...
Bone Biologics Corporation announced a private placement deal raising $3 million upfront by issuing common stock and warrants priced at $1.42 each. The company may raise an additional $6 million if all warrants are exercised by July 2026. Proceeds wi...
